Insider Buying: TELA Bio (NASDAQ:TELA) CEO Purchases $10,500.00 in Stock

TELA Bio, Inc. (NASDAQ:TELA) CEO Heather Getz purchased 15,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were acquired at an average cost of $0.70 per share, for a total transaction of $10,500.00. Following the transaction, the chief executive officer owned 520,000 shares of the company’s stock, valued at $364,000. This trade represents a 2.97% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

TELA Bio Stock Up 0.9%

Shares of NASDAQ:TELA traded up $0.01 during trading on Monday, hitting $0.65. 241,010 shares of the company’s stock traded hands, compared to its average volume of 166,260. TELA Bio, Inc. has a 52 week low of $0.50 and a 52 week high of $2.00. The company has a current ratio of 2.99, a quick ratio of 2.38 and a debt-to-equity ratio of 8.82. The company has a market cap of $29.18 million, a price-to-earnings ratio of -0.84 and a beta of 1.34. The company has a 50-day moving average price of $0.78 and a 200-day moving average price of $0.80.

TELA Bio (NASDAQ:TELA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. The business had revenue of $19.29 million during the quarter, compared to analyst estimates of $20.01 million. As a group, research analysts forecast that TELA Bio, Inc. will post -0.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TELA Bio in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $2.20.

Institutional Investors Weigh In On TELA Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of TELA. Essex Woodlands Management Inc. boosted its holdings in shares of TELA Bio by 87.7% in the 4th quarter. Essex Woodlands Management Inc. now owns 7,714,709 shares of the company’s stock valued at $9,103,000 after buying an additional 3,604,000 shares during the last quarter. Perkins Capital Management Inc. increased its holdings in TELA Bio by 67.6% during the fourth quarter. Perkins Capital Management Inc. now owns 1,397,418 shares of the company’s stock worth $1,649,000 after buying an additional 563,490 shares during the last quarter. BlackRock Inc. bought a new stake in TELA Bio during the second quarter worth $281,000. UP Strategic Wealth Investment Advisors LLC bought a new stake in TELA Bio during the second quarter worth $91,000. Finally, WealthTrust Axiom LLC lifted its stake in TELA Bio by 39.1% in the fourth quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company’s stock valued at $381,000 after acquiring an additional 90,650 shares during the last quarter. Institutional investors and hedge funds own 94.35% of the company’s stock.

TELA Bio Company Profile

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.